焦虑和抑郁心理状态对糖尿病肾病影响的研究进展

doi:10.3969/j.issn.1004-583X.2021.11.014

摘要/Abstract

摘要：

糖尿病肾病(diabetic nephropathy, DN)是糖尿病主要的微血管并发症之一,亦是导致终末期肾脏病(end-stage renal disease, ESRD)的主要病因,现已成为全球性的公共卫生问题。DN患者出现临床症状和病理损害的同时,还常伴发焦虑、抑郁等心理症状。近年来研究显示,焦虑和抑郁状态可能负面影响DN患者肾脏代谢功能,增加血液净化或死亡风险,进而严重影响患者治疗效果和预后。因此,临床中重视及改善DN患者心理问题至关重要。本文就DN患者并发焦虑、抑郁的流行病学、临床特征、危险因素、不良预后、病理生理机制以及治疗等方面的新进展进行综述, 为这一心身疾病的临床诊治提供参考。

关键词: 糖尿病肾病, 焦虑, 抑郁, 心理

中图分类号:

R587.24

沈琰, 黄诗纯, 陈怡, 詹明. 焦虑和抑郁心理状态对糖尿病肾病影响的研究进展[J]. 临床荟萃, 2021, 36(11): 1029-1033.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.11.014

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I11/1029

参考文献 41

[1]	Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract, 2017, 128:40-50. doi: 10.1016/j.diabres.2017.03.024 URL
[2]	Umanath K, Lewis JB. Update on diabetic nephropathy: Core curriculum 2018[J]. Am J Kidney Dis, 2018, 71(6):884-895. doi: S0272-6386(17)31102-2 pmid: 29398179
[3]	Kittiskulnam P, Sheshadri A, Johansen KL. Consequences of CKD on functioning[J]. Semin Nephrol, 2016, 36(4):305-318. doi: 10.1016/j.semnephrol.2016.05.007 pmid: 27475661
[4]	Mendes R, Martins S, Fernandes L. Adherence to medication, physical activity and diet in older adults with diabetes: Its association with cognition, anxiety and depression[J]. J Clin Med Res, 2019, 11(8):583-592. doi: 10.14740/jocmr3894 pmid: 31413770
[5]	Huang M, Liu Y, Wang J, et al. High rates of depression anxiety and suicidal ideation among inpatients in general hospital in China[J]. Int J Psychiatry Clin Pract, 2019, 23(2):99-105. doi: 10.1080/13651501.2018.1539179 URL
[6]	Stanton R, Rosenbaum S, Rebar A, et al. Prevalence of chronic health conditions in Australian adults with depression and/or anxiety[J]. Issues Ment Health Nurs, 2019, 40(10):902-907. doi: 10.1080/01612840.2019.1613701 URL
[7]	熊莉, 马文. 慢性阻塞性肺疾病合并焦虑、抑郁的诊断及治疗进展[J]. 疑难病杂志, 2021, 20(11):1173-1177.
[8]	Rees G, Xie J, Fenwick EK, et al. Association between diabetes-related eye complications and symptoms of anxiety and depression[J]. JAMA Ophthalmol, 2016, 134(9):1007-1014. doi: 10.1001/jamaophthalmol.2016.2213 URL
[9]	Khaledi M, Haghighatdoost F, Feizi A, et al. The prevalence of comorbid depression in patients with type 2 diabetes: An updated systematic review and meta-analysis on huge number of observational studies[J]. Acta Diabetol, 2019, 56(6):631-650. doi: 10.1007/s00592-019-01295-9 URL
[10]	Pan S, Liu ZW, Shi S, et al. Hamilton rating scale for depression-24 (HAM-D24) as a novel predictor for diabetic microvascular complications in type 2 diabetes mellitus patients[J]. Psychiatry Res, 2017, 258:177-183. doi: 10.1016/j.psychres.2017.07.050 URL
[11]	Sharif S, Raza MT, Mushtaq S, et al. Frequency of depression in patients with type 2 diabetes mellitus and its relationship with glycemic control and diabetic microvascular complications[J]. Cureus, 2019, 11(7):e5145.
[12]	Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016, 375(9):905-906. doi: 10.1056/NEJMc1602469 URL
[13]	Mosleh H, Alenezi M, Al Johani S, et al. Prevalence and factors of anxiety and depression in chronic kidney disease patients undergoing hemodialysis: A cross-sectional single-center study in Saudi Arabia[J]. Cureus, 2020, 12(1):e6668. doi: 10.7759/cureus.6668 pmid: 31976185
[14]	Chan KM, Cheung CY, Chan YH, et al. Prevalence and impact of anxiety and depression in Chinese peritoneal dialysis patients: A single centre study[J]. Nephrology (Carlton), 2018, 23(2):155-161. doi: 10.1111/nep.2018.23.issue-2 URL
[15]	Unsal Avdal E, Ayvaz I, Özgursoy Uran BN, et al. Opinions of hemodialysis and peritoneum patients regarding depression and psychological problems which they experience: A qualitative study[J]. J Infect Public Health, 2020, 13(12):1988-1992. doi: 10.1016/j.jiph.2020.02.041 URL
[16]	Shirazian S, Grant CD, Aina O, et al. Depression in chronic kidney disease and end-stage renal disease: Similarities and differences in diagnosis, epidemiology, and management[J]. Kidney Int Rep, 2016, 2(1):94-107.
[17]	Cohen SD, Cukor D, Kimmel PL. Anxiety in patients treated with hemodialysis[J]. Clin J Am Soc Nephrol, 2016, 11(12):2250-2255. doi: 10.2215/CJN.02590316 URL
[18]	Pu L, Zou Y, Wu SK, et al. Prevalence and associated factors of depressive symptoms among chronic kidney disease patients in China: Results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)[J]. J Psychosom Res, 2020, 128:109869.
[19]	Sun N, Lou P, Shang Y, et al. Prevalence and determinants of depressive and anxiety symptoms in adults with type 2 diabetes in China: A cross-sectional study[J]. BMJ Open, 2016, 6(8):e012540.
[20]	Takasaki K, Babazono T, Ishizawa K, et al. Relationship between diabetic nephropathy and depression: A cross-sectional analysis using the Diabetes Study from the Center of Tokyo Women's Medical University (DIACET)[J]. BMJ Open Diabetes Res Care, 2016, 4(1):e000310.
[21]	Aggarwal HK, Jain D, Dabas G, et al. Prevalence of depression, anxiety and insomnia in chronic kidney disease patients and their co-relation with the demographic variables[J]. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 2017, 38(2):35-44. doi: 10.1515/prilozi-2017-0020 pmid: 28991772
[22]	Zheng G, Wen J, Lu H, et al. Elevated global cerebral blood flow, oxygen extraction fraction and unchanged metabolic rate of oxygen in young adults with end-stage renal disease: An MRI study[J]. Eur Radiol, 2016, 26(6):1732-1741. doi: 10.1007/s00330-015-3968-9 pmid: 26334507
[23]	Loosman WL, Rottier MA, Honig A, et al. Association of depressive and anxiety symptoms with adverse events in Dutch chronic kidney disease patients: A prospective cohort study[J]. BMC Nephrol, 2015, 16:155. doi: 10.1186/s12882-015-0149-7 pmid: 26390864
[24]	Adibfar A, Saleem M, Lanctot KL, et al. Potential biomarkers for depression associated with coronary artery disease: A critical review[J]. Curr Mol Med, 2016, 16(2):137-164. pmid: 26812919
[25]	Lampropoulou IT, Stangou M, Sarafidis P, et al. TNF-α pathway and T-cell immunity are activated early during the development of diabetic nephropathy in type II diabetes mellitus[J]. Clin Immunol, 2020, 215:108423.
[26]	Simões E Silva AC, Miranda AS, Rocha NP, et al. Neuropsychiatric disorders in chronic kidney disease[J]. Front Pharmacol, 2019, 10:932. doi: 10.3389/fphar.2019.00932 URL
[27]	Deschênes SS, Burns RJ, Schmitz N. Comorbid depressive and anxiety symptoms and the risk of type 2 diabetes: Findings from the lifelines cohort study[J]. J Affect Disord, 2018, 238:24-31. doi: 10.1016/j.jad.2018.05.029 URL
[28]	Goh ZS, Griva K. Anxiety and depression in patients with end-stage renal disease: Impact and management challenges-A narrative review[J]. Int J Nephrol Renovasc Dis, 2018, 11:93-102. doi: 10.2147/IJNRD URL
[29]	Tafet GE, Nemeroff CB. Pharmacological treatment of anxiety disorders: The role of the HPA axis[J]. Front Psychiatry, 2020, 11:443.
[30]	Huo R, Zeng BH, Zeng L, et al. Microbiota modulate anxiety-like behavior and endocrine abnormalities in hypothalamic-pituitary-adrenal axis[J]. Front Cell Infect Microbiol, 2017, 7:489. doi: 10.3389/fcimb.2017.00489 URL
[31]	Diaz Bustamante L, Ghattas KN, Ilyas S, et al. Does treatment for depression with collaborative care improve the glycemic levels in diabetic patients with depression? A systematic review[J]. Cureus, 2020, 12(9):e10551.
[32]	Zahed NS, Sharifi M, Karimi M, et al. Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression[J]. J Renal Inj Prev, 2016, 6(1):65-69. doi: 10.15171/jrip.2017.12 URL
[33]	Yuan P, Zhang J, Li L, et al. Fluoxetine attenuated anxiety-like behaviors in streptozotocin-induced diabetic mice by mitigating the inflammation[J]. Mediators Inflamm, 2019, 2019:4315038.
[34]	Kessing LV, Rytgaard HC, Ekstrøm CT, et al. Antidiabetes agents and incident depression: A nationwide population-based study[J]. Diabetes Care, 2020, 43(12):3050-3060. doi: 10.2337/dc20-1561 pmid: 32978179
[35]	Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants[J]. Expert Opin Drug Metab Toxicol, 2019, 15(10):831-847. doi: 10.1080/17425255.2019.1669560 URL
[36]	Natale P, Palmer SC, Ruospo M, et al. Psychosocial interventions for preventing and treating depression in dialysis patients[J]. Cochrane Database Syst Rev, 2019, 12(12): CD004542.
[37]	Powers MB, de Kleine RA, Smits JAJ. Core Mechanisms of Cognitive Behavioral Therapy for Anxiety and Depression: A Review[J]. Psychiatr Clin North Am, 2017, 40(4):611-623. doi: 10.1016/j.psc.2017.08.010 URL
[38]	Valsaraj BP, Bhat SM, Latha KS. Cognitive behaviour therapy for anxiety and depression among people undergoing haemodialysis: A randomized control trial[J]. J Clin Diagn Res, 2016, 10(8): VC06-VC10.
[39]	Chan R, Dear BF, Titov N, et al. Examining internet-delivered cognitive behaviour therapy for patients with chronic kidney disease on haemodialysis: A feasibility open trial[J]. J Psychosom Res, 2016, 89:78-84. doi: 10.1016/j.jpsychores.2016.08.012 URL
[40]	Armani Kian A, Vahdani B, Noorbala AA, et al. The impact of mindfulness-based stress reduction on emotional wellbeing and glycemic control of patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2018, 2018:1986820.
[41]	Zhu FX, Zhang XY, Ding XK, et al. Protective effect of regular physical activity on major depressive episodes in patients with early stages of chronic kidney disease[J]. Ren Fail, 2017, 39(1):602-606. doi: 10.1080/0886022X.2017.1361833 URL

焦虑和抑郁心理状态对糖尿病肾病影响的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	龚财芳, 赵俊宇, 游川. 接纳与承诺疗法对癌症患者心理健康和生活质量影响的meta分析[J]. 临床荟萃, 2024, 39(2): 101-107.
[2]	原风英, 马晓玲, 曲军民. 阿戈美拉汀结合扑克牌类娱疗对首发重度抑郁症患者认知功能的影响[J]. 临床荟萃, 2024, 39(2): 130-133.
[3]	储丽清, 杨敏. 运动疗法在慢性肾脏病中的应用进展[J]. 临床荟萃, 2024, 39(2): 183-187.
[4]	王海婷, 张丽平, 武雪瑞, 包利红, 李维燕, 闫进琳, 宋淑华, 卢珊珊. 远程康复在脊髓损伤患者居家康复护理中的研究进展[J]. 临床荟萃, 2023, 38(9): 851-854.
[5]	杨鑫, 许华娇. 基于Web of Science糖尿病患者心理干预研究的文献计量学分析[J]. 临床荟萃, 2023, 38(8): 731-736.
[6]	孙佳宁, 崔轶霞. 类风湿关节炎与抑郁症共病的研究进展[J]. 临床荟萃, 2023, 38(7): 663-667.
[7]	陈婷, 刘金彦. 中药靶向PI3K/Akt/mTOR通路调节自噬在糖尿病肾脏病中的研究进展[J]. 临床荟萃, 2023, 38(6): 564-568.
[8]	高秦宇, 包蓓艳, 金燕, 赵宇. IgA肾病合并抑郁状态患者的临床特征和预后影响因素分析[J]. 临床荟萃, 2023, 38(6): 510-515.
[9]	吴亚楠, 延天美, 梁鹏, 魏立民. 中老年糖尿病患者抑郁症状的高危识别[J]. 临床荟萃, 2023, 38(6): 516-520.
[10]	李亚, 杜涛明, 邱世香, 陈超, 钟立明. 伴有抑郁症状肝癌患者脑功能连接研究[J]. 临床荟萃, 2023, 38(6): 532-536.
[11]	段登艾, 邓燕, 张志雄, 谷樟林. 辩证行为疗法联合舍曲林对伴有非自杀性自伤的青少年抑郁障碍患者的影响[J]. 临床荟萃, 2023, 38(4): 319-323.
[12]	李会芳, 苗霞. 甲状腺激素水平对2型糖尿病肾脏病风险的预测[J]. 临床荟萃, 2023, 38(2): 137-142.
[13]	王璐璐, 董露露, 江超, 王九雪, 常雅君, 王天俊. 弥散张量成像评估帕金森病合并非运动症状患者脑微结构的研究进展[J]. 临床荟萃, 2023, 38(2): 189-192.
[14]	吕静静, 李静, 郑华城. 儿童抽动障碍与精神心理及环境因素的研究进展[J]. 临床荟萃, 2023, 38(11): 1031-1033.
[15]	王翠, 林昊, 武萍萍, 张雅丽, 任建, 徐婷, 董国玉, 宰国田. 2型糖尿病患者高同型半胱氨酸血症与早期肾脏疾病的相关性[J]. 临床荟萃, 2023, 38(1): 42-45.